These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35660539)

  • 21. Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease.
    Hung AM; Assimon VA; Chen HC; Yu Z; Vlasschaert C; Triozzi JL; Chan H; Wheless L; Wilson O; Shah SC; Mack T; Thompson T; Matheny ME; Chandrasekar S; Mozaffari SV; Chung CP; Tsao P; Susztak K; Siew ED; Estrada K; Gaziano JM; Graham RR; Tao R; Hoek M; Robinson-Cohen C; Green EM; Bick AG;
    J Am Soc Nephrol; 2023 Nov; 34(11):1889-1899. PubMed ID: 37798822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of APOL1 With Heart Failure With Preserved Ejection Fraction in Postmenopausal African American Women.
    Franceschini N; Kopp JB; Barac A; Martin LW; Li Y; Qian H; Reiner AP; Pollak M; Wallace RB; Rosamond WD; Winkler CA
    JAMA Cardiol; 2018 Aug; 3(8):712-720. PubMed ID: 29971324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Values Affirmation on Reducing Racial Differences in Adherence to Hypertension Medication: The HYVALUE Randomized Clinical Trial.
    Daugherty SL; Helmkamp L; Vupputuri S; Hanratty R; Steiner JF; Blair IV; Dickinson LM; Maertens JA; Havranek EP
    JAMA Netw Open; 2021 Dec; 4(12):e2139533. PubMed ID: 34913976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apolipoprotein L1 Variants and Blood Pressure Traits in African Americans.
    Nadkarni GN; Galarneau G; Ellis SB; Nadukuru R; Zhang J; Scott SA; Schurmann C; Li R; Rasmussen-Torvik LJ; Kho AN; Hayes MG; Pacheco JA; Manolio TA; Chisholm RL; Roden DM; Denny JC; Kenny EE; Bottinger EP
    J Am Coll Cardiol; 2017 Mar; 69(12):1564-1574. PubMed ID: 28335839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementation of a culturally competent
    Smith JD; Agrawal A; Wicklund C; Duquette D; Friedewald J; Rasmussen LV; Gacki-Smith J; Tandon SD; Muhammad LN; Yancy CW; Dong S; Cooper M; Gilbert A; Shetty A; Gordon EJ
    BMJ Open; 2023 May; 13(5):e067657. PubMed ID: 37188469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of
    Bick AG; Akwo E; Robinson-Cohen C; Lee K; Lynch J; Assimes TL; DuVall S; Edwards T; Fang H; Freiberg SM; Giri A; Huffman JE; Huang J; Hull L; Kember RL; Klarin D; Lee JS; Levin M; Miller DR; Natarajan P; Saleheen D; Shao Q; Sun YV; Tang H; Wilson O; Chang KM; Cho K; Concato J; Gaziano JM; Kathiresan S; O'Donnell CJ; Rader DJ; Tsao PS; Wilson PW; Hung AM; Damrauer SM;
    Circulation; 2019 Sep; 140(12):1031-1040. PubMed ID: 31337231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).
    Ambrosius WT; Sink KM; Foy CG; Berlowitz DR; Cheung AK; Cushman WC; Fine LJ; Goff DC; Johnson KC; Killeen AA; Lewis CE; Oparil S; Reboussin DM; Rocco MV; Snyder JK; Williamson JD; Wright JT; Whelton PK;
    Clin Trials; 2014 Oct; 11(5):532-46. PubMed ID: 24902920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma apolipoprotein L1 levels do not correlate with CKD.
    Bruggeman LA; O'Toole JF; Ross MD; Madhavan SM; Smurzynski M; Wu K; Bosch RJ; Gupta S; Pollak MR; Sedor JR; Kalayjian RC
    J Am Soc Nephrol; 2014 Mar; 25(3):634-44. PubMed ID: 24231663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of Injury in APOL1-associated Kidney Disease.
    Ma L; Divers J; Freedman BI
    Transplantation; 2019 Mar; 103(3):487-492. PubMed ID: 30371607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum 6-Bromotryptophan Levels Identified as a Risk Factor for CKD Progression.
    Tin A; Nadkarni G; Evans AM; Winkler CA; Bottinger E; Rebholz CM; Sarnak MJ; Inker LA; Levey AS; Lipkowitz MS; Appel LJ; Arking DE; Coresh J; Grams ME
    J Am Soc Nephrol; 2018 Jul; 29(7):1939-1947. PubMed ID: 29777021
    [No Abstract]   [Full Text] [Related]  

  • 32. Race, APOL1 Risk Variants, and Clinical Outcomes among Older Adults: The ARIC Study.
    Chen TK; Coresh J; Daya N; Ballew SH; Tin A; Crews DC; Grams ME
    J Am Geriatr Soc; 2021 Jan; 69(1):155-163. PubMed ID: 32894582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. APOL1 risk alleles among individuals with CKD in Northern Tanzania: A pilot study.
    Stanifer JW; Karia F; Maro V; Kilonzo K; Qin X; Patel UD; Hauser ER
    PLoS One; 2017; 12(7):e0181811. PubMed ID: 28732083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial.
    Langefeld CD; Divers J; Pajewski NM; Hawfield AT; Reboussin DM; Bild DE; Kaysen GA; Kimmel PL; Raj DS; Ricardo AC; Wright JT; Sedor JR; Rocco MV; Freedman BI;
    Kidney Int; 2015 Jan; 87(1):169-75. PubMed ID: 25029429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. APOL1 Genotype and Glomerular and Tubular Kidney Injury in Women With HIV.
    Jotwani V; Shlipak MG; Scherzer R; Parekh RS; Kao WH; Bennett M; Cohen MH; Nowicki M; Sharma A; Young M; Tien PC; Parikh CR; Estrella MM
    Am J Kidney Dis; 2015 Jun; 65(6):889-98. PubMed ID: 25921719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. APOL1 risk variants, race, and progression of chronic kidney disease.
    Parsa A; Kao WH; Xie D; Astor BC; Li M; Hsu CY; Feldman HI; Parekh RS; Kusek JW; Greene TH; Fink JC; Anderson AH; Choi MJ; Wright JT; Lash JP; Freedman BI; Ojo A; Winkler CA; Raj DS; Kopp JB; He J; Jensvold NG; Tao K; Lipkowitz MS; Appel LJ; ;
    N Engl J Med; 2013 Dec; 369(23):2183-96. PubMed ID: 24206458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.
    Gong Y; McDonough CW; Wang Z; Hou W; Cooper-DeHoff RM; Langaee TY; Beitelshees AL; Chapman AB; Gums JG; Bailey KR; Boerwinkle E; Turner ST; Johnson JA
    Circ Cardiovasc Genet; 2012 Dec; 5(6):686-91. PubMed ID: 23087401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. African American Living Donors' Attitudes About APOL1 Genetic Testing: A Mixed Methods Study.
    Gordon EJ; Amόrtegui D; Blancas I; Wicklund C; Friedewald J; Sharp RR
    Am J Kidney Dis; 2018 Dec; 72(6):819-833. PubMed ID: 30360961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pharmacist based intervention to improve the care of patients with CKD: a pragmatic, randomized, controlled trial.
    Cooney D; Moon H; Liu Y; Miller RT; Perzynski A; Watts B; Drawz PE
    BMC Nephrol; 2015 Apr; 16():56. PubMed ID: 25881226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low prevalence of apolipoprotein L1 gene variants in Black South Africans with hypertension-attributed chronic kidney disease
.
    Nqebelele NU; Dickens C; Dix-Peek T; Duarte R; Naicker S
    Clin Nephrol; 2019 Jan; 91(1):40-47. PubMed ID: 30369398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.